A randomized trial of the effects of flaxseed to manage constipation, weight, glycemia, and lipids in constipated patients with type 2 diabetes - PubMed (original) (raw)

A randomized trial of the effects of flaxseed to manage constipation, weight, glycemia, and lipids in constipated patients with type 2 diabetes

Noureddin Soltanian et al. Nutr Metab (Lond). 2018.

Abstract

Background: To compare the effects of baked flaxseed versus those who received a placebo on constipation symptom scores, weight, glycemic and lipid control in constipated patients with type 2 diabetes (T2D).

Methods: In a single-blinded, randomized controlled trial, 53 constipated patients with T2D with body mass index (BMI) 20.5-48.9 kg/m2 received either 10 g of flaxseed pre-mixed in cookies twice per day or placebo cookies for 12 weeks. The constipation symptom scores, BMI, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and lipid profile were determined at the beginning and end of 4, 8, and 12-week period. Constipation was evaluated with a stool diary (ROME III).

Results: After the 12-week intervention, constipation symptom scores (2.46), weight (- 3.8 kg), BMI (- 1.5 kg/m2), FPG (- 26.7 mg/dl), cholesterol (- 37.3 mg/dl), triglycerides (- 10.4 mg/dl), LDLC (- 21.0 mg/dl), HDLC (4.7 mg/dl), cholesterol/ HDLC ratio (- 1.4 mg/dl) significantly decreased from baseline in the flaxseed group (all _P_-values < 0.05). The differences of absolute change of constipation symptom scores (2.46 vs. 0.41), weight (- 3.8 vs. 0.0 kg), BMI (- 1.5 vs.-0.1 kg/m2), FPG (- 26.7 vs.-1.9 mg/dl), >HbA1c (- 0.8 vs. 1.0%), cholesterol (- 37.3 vs. -10.4 mg/dl), LDLC (- 21.0 vs. -4.3 mg/dl), and HDLC (4.7 vs. -4.4 mg/dl) between the flaxseed and placebo groups were statistically significant (all _P_-values < 0.05). The compliance was good and no adverse effects were observed.

Conclusion: In constipated patients with T2D, flaxseed cookies used as a snack may be a useful tool for decreasing constipation symptoms, weight, glycemic and lipid levels.

Trial registration: irct.ir: IRCT20110416006202N2.

Keywords: Constipation; Diabetes; Efficacy; Flaxseed; Glucose; Lipid.

PubMed Disclaimer

Conflict of interest statement

Written informed consent for the publication was obtained from the Participants.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1

Fig. 1

Design of the study

Similar articles

Cited by

References

    1. International Diabetes Federation . IDF Diabetes Atlas. 7. Brussels: International Diabetes Federation; 2015. - PubMed
    1. Maisey A. A practical approach to gastrointestinal complications of diabetes. Diabetes Ther. 2016;7:379–386. doi: 10.1007/s13300-016-0182-y. - DOI - PMC - PubMed
    1. Maleki D, Locke GR, Camilleri M, Zinsmeister AR, Yawn BP, Leibson C, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med. 2000;160:2808–2816. doi: 10.1001/archinte.160.18.2808. - DOI - PubMed
    1. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol. 2002;97:604–611. doi: 10.1111/j.1572-0241.2002.05537.x. - DOI - PubMed
    1. Johanson JF, Kralstein J. Chronic constipation: a survey of the patients perspective. Aliment Pharmacol Ther. 2007;25:599–608. doi: 10.1111/j.1365-2036.2006.03238.x. - DOI - PubMed

LinkOut - more resources